Type 2 & other diabetes

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus

Cardiovasc DiabetolPublished Observational cohort study

An erratum to this article was published (Cardiovasc Diabetol, 5 Sep 2023 ↗)

Main finding · MACEResult — go to the resultHazard ratio 0.99 95% CI 0.46–2.14

Authors' conclusion

Our findings demonstrated that SGLT2i did not influence the rate of MACEs compared with DPP-4i in combination with metformin in diabetic patients with AMI but did improve left ventricular ejection fraction.

Study context

Population
Diabetic patients with acute MI from a Korean nationwide multicenter observational cohort
Participants
779 patients
Exposure
Metformin plus SGLT2i vs metformin plus DPP-4i
  • SGLT2in = 186
  • DPP-4in = 593reference
Outcome
MACE: composite of all-cause mortality, non-fatal MI, any revascularization, cerebrovascular accident and stent thrombosis
Follow-up
One year
Methodological detailsnationwide multicenter, inverse probability of treatment weighting (IPTW)
  • Nationwide multicenter
  • Inverse probability of treatment weighting (IPTW)

Main finding

MACE

Hazard ratio

0.99

95% CI 0.46–2.14

P = 0.983

SGLT2ivs DPP-4i
HR 0.99 (95% CI 0.46–2.14); P = 0.983

As reported in the abstract

Observational data: associations, not effects.

Further findings

OutcomeSGLT2iDPP-4iP value
Left ventricular ejection fraction improvement (exploratory), before statistical balancingExploratory analysis6.10 ± 8.302.95 ± 10.34P = 0.007
Left ventricular ejection fraction improvement (exploratory), after IPTWExploratory analysis6.91 ± 8.913.13 ± 10.41P = 0.027

All clinical outcome items

All items for clinical outcomes comparable between the two groups in unadjusted and adjusted analyses

Original publication

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus. Cardiovasc Diabetol. Published 22 July 2023. doi:10.1186/s12933-023-01914-4

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.